Date

May 16, 2022

 

The Commission on Life Science will meet on May, 16 to evaluate the best startups in the sector.

The startups selected to participate in UniCredit Start Lab 2022 will be offered several opportunities, including: 

  • participation in meetings with UniCredit Corporate clients in order to evaluate potential commercial/industrial/technological partnerships, both in ad hoc sectoral initiatives and in one-to-one meetings;
  • opportunity to get in touch with possible investors, including international ones, in dedicated initiatives;
  • access to the Startup Academy and other initiatives as part of the coaching and managerial training program organized by the UniCredit Start Lab team;
  • guidance from professional Mentors, consultants and entrepreneurs, who will help them develop their businesses by offering skills and providing access to networks;
  • the assignment of a dedicated UniCredit manager.

The winner will also receive a cash prize of €10,000.

The ten finalists are as follows:

AICUBE

AICube wants to enhance the level of secondary prevention of several NCD diseases measuring specific biomarkers on a daily basis to gain statistically significant data through a patented device that collects a saliva sample in non-invasive mode by means of an "augmented" electric toothbrush.

AORTICLAB

AorticLab is a startup that aims to innovate and improve the treatment of patients suffering from aortic valve stenosis. It is currently developing a safe and low invasive system for the functional restoration of the native aortic valve affected by calcific dystrophy.

DORIAN TECHNOLOGIES

Dorian Technologies provides easy access to the most advanced quantitative-imaging techniques based on radiomics and AI in the medical field. By leveraging cloud computing, the platform transforms any customer device into an advanced imaging laboratory, cutting down time and diagnostic error.

D-TAILS

D-TAILS researches and develops methods for the early diagnosis of Alzheimer's disease (by monitoring specific protein aggregates through retinal observation) and for the mass screening of breast and prostate cancer (technique derived from C.elegans receptors that shows repetitive and specific behaviour when exposed to patients' urine with 99% accuracy).

HEMERA

Hemera is a regenerative medicine new venture and high research project. The solution, based on reprogrammed cells with precise instructions, promotes the regeneration of nervous tissue and the creation of a useful therapy to repair spinal injuries. Hemera is a spin-off of the Universities of Verona and the State University of Milan and collaborates with researchers from the Humanitas Clinical Institute.

MOVEO

Moveo has developed a self-powered, extremely lightweight soft exosuit to augment walking by people with limited mobility, named ExoBand. ExoBand is designed for those whose walking ability has been affected by degenerative disease, age or injury, allowing them to walk further with less energy expenditure.

RESALIS

Resalis Therapeutics is dedicated to the in-depth understanding of microRNA biology and to the design of safe and effective miRNA targeted therapies, by developing first-in-class antisense oligonucleotides to address highly unmet medical needs in liver diseases, metabolic disorders and cancer, using a multi-pathway epigenetic approach.

SIBYLLA BIOTECH

Sibylla Biotech is an early-stage drug discovery company producing folding interfering small molecule degraders (FIDs) as new therapeutics for untreatable diseases. Well-differentiated against other degraders and of use in any therapeutic area, Sibylla's internal pipeline FIDs target folding intermediates states, using a proprietary platform developed by the founders.

SURGIQ

SurgiQ uses artificial intelligence to help private and public healthcare providers improve their operational efficiency and ensure effective care for an increasing number of patients. It makes time-consuming and complex tasks such as surgery and rehabilitation planning semi-automated, ensuring better use of resources.

SYNDIAG

SynDiag is an innovative startup, born to lead the digital transformation in diagnostic ultrasound. SynDiag's technology accompanies gynecologists and patients throughout the diagnosis of ovarian cancer, and it is thanks to Artificial Intelligence that sonography becomes the most important imaging for early diagnosis.

 

Stay tuned to find out who wins!